Adrecizumab, first-in-class monoclonal antibody, targets the vasoprotective peptide Adrenomedullin, to treat conditions associated with increased vascular leakage, congestion and shock. Currently under clinical evaluation in the AdrenOSS-2 trial, a biomarker-guided, double-blind, placebo-controlled, randomized, multicenter proof-of-concept Phase 2 trial, in 300 septic shock patients (completed enrollment as of Sept 2019) – data expected 1Q 2020. Excellent safety and tolerability demonstrated in two Phase I trials.
Cardiovascular, Rare Disease
Berlin, Berlin 16761
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.